https://www.selleckchem.com/pr....oducts/proteinase-k.
09 (20.3; 36.6) for on-demand patients (n=14). Median total ABRs for 2×W (n=23), E5D (n=33), E7D (n=23) and variable frequency (n=28) groups were 1.57, 1.17, 0.65 and 3.10, respectively. Of prophylaxis patients, 20.6% were bleed-free during the entire extension (median time, 3.2years) and 50.0% were bleed-free during the last 6months. No patient developed FVIII inhibitors. No deaths or thrombotic events were reported. Efficacy and safety of BAY 94-9027 was confirmed, with extension data supporting its use as a long-term treatment o
Like
Comment
Share
